CurifyLabs secures $14 million to produce personalised medicine through 3D printing.
Your prescription, custom-made. A Finnish startup aims to transform the back area of your pharmacy into a compact, automated drug production facility and has secured $14 million to facilitate this in the United States.
CurifyLabs has announced the completion of a $14 million (€12 million) Series A funding round. Based in Helsinki, the company develops machines and software that enable pharmacies to 3D-print customized medications on-site. This funding will help the firm expand further into the U.S., where its technology is already operational in pharmacies across 21 states.
Personalized medication production
Most medications are available in standard doses. However, children, elderly patients, and individuals with rare medical conditions often require tailored solutions or different forms entirely. Traditionally, pharmacists have manually compounded these medicines, a slow and error-prone process.
CurifyLabs streamlines this process. Its system combines software with pharmaceutical-grade ingredient bases and a 3D printer to create customized doses with integrated quality checks.
According to the company, their latest printer, the PharmaPrinter Aurum, can compound medications up to nine times faster than manual methods. The technology holds ISO 13485 certification and adheres to U.S. FDA regulations for non-sterile compounding.
The heart of EU tech
Get the latest updates from the EU tech landscape, insights from our perceptive founder Boris, and some questionable AI-generated art straight to your inbox every week for free. Sign up now!
A Nordic investment in the U.S. market
The funding round was co-led by Sandwater and HealthCap, with participation from Finland’s state investor Tesi and returning investor Lifeline Ventures. Several U.S. clients and team members also contributed. The funds will be directed toward U.S. expansion, supply chain logistics, customer support, and research.
“Their progress in the U.S. demonstrates that Finnish health technology can compete effectively on the global stage,” stated Joni Karsikas of Tesi. This reflects a common aspiration in the Nordics, where companies like Espoo's IQM are also entering the New York market, and numerous deep-tech firms from the region are expanding into the U.S.
Small funding round, vast opportunities
Founded in 2021 by CEO Charlotta Topelius and pharmaceutical scientist Niklas Sandler, CurifyLabs has built upon a previous €6.7 million funding round from last year. Though this amount is modest compared to the multi-trillion dollar pharmaceutical market, automating its more intricate processes represents a viable business opportunity.
Others are pursuing similar advancements, ranging from pharmacist-free dispensaries to a surge of European drug-tech investments and large-scale public precision medicine initiatives. While personalized medicine has been “on the verge” for years, CurifyLabs is optimistic that it will finally become a reality, one printed dose at a time.
Other articles
Thought Machine reaches $100 million in revenue, postpones IPO to 2028.
The UK core-banking company Thought Machine has surpassed $100 million in revenue and annual recurring revenue (ARR), secured £30 million from a banking client, and delayed its stock market listing until 2028.
CurifyLabs secures $14 million to 3D-print customized medicine.
Finland's CurifyLabs has secured $14 million in Series A funding to grow its presence in the US, where pharmacies across 21 states utilize its 3D printers to produce personalized medicine doses.
Hedge funds have offloaded chip stocks for the fourth consecutive week, but they have not reduced their positions in AI investments.
According to data from Goldman Sachs, semiconductors remained the US sector with the highest net sales for the fourth consecutive week, although hedge funds' positions in AI continue to be near all-time highs.
Even Realities reaches $1 billion in sales with their camera-free smart glasses.
Shenzhen's Even Realities has secured $150 million from Meituan and Tencent, reaching a valuation of $1 billion for its camera-free smart glasses, positioning itself as a competitor to Meta.
Worldmodeldata secures £7M to develop AI training using video games.
The Cambridge-based startup Worldmodeldata has secured £7 million in seed funding, led by Iona Star Capital, to convert licensed video game data into training datasets for AI world models.
The time capsule for America’s 250th anniversary contains an iPhone 17 Pro Max.
The time capsule for America's 250th anniversary contains an iPhone 17 Pro Max, a prediction generated by AI, and numerous historical artifacts intended to symbolize life in 2026.
CurifyLabs secures $14 million to produce personalised medicine through 3D printing.
Finland's CurifyLabs has secured $14 million in Series A funding to grow in the US, where pharmacies across 21 states utilize its 3D printers to create personalized medication doses.